Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

A Phase 1/2a, First-in-human Study to Evaluate BMS-986470 in Healthy Volunteers and Participants with Sickle Cell Disease Recruiting

2023-510283-12-00 Sickle Cell Disease 2025-06-12
A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting

2024-511534-12-00 Advanced or Metastatic Solid Tumours 2025-06-10
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours Recruiting

2024-519184-18-00 Advanced Solid Tumour 2025-05-30
Randomized, controlled, multicenter Phase I/II study comparing the safety and immunogenicity of a booster dose of an intranasal COVID-19 vac… Recruiting

2024-510589-17-00 Healthy volunteers 2025-05-09
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) i… Recruiting

2023-507613-10-01 Active Systemic Lupus Erythematosus;Systemic lupus eryt 2025-03-31
First -in-Human Study of DS-3939a in Subjects with Advanced Solid Tumors Recruiting

2023-507937-14-00 Metastatic Solid Tumor 2025-03-25
Dose escalation of allogeneic Adipose derived Stroma/stem Cells for the treatment of Crohn’s fistula Recruiting

2024-511821-75-00 Crohn’s fistula 2025-03-13
Eight-Treg study: a phase I dose escalation trial of adoptive immunotherapy with autologous ex vivo expanded regulatory CD8+ T cells in livi… Recruiting

2024-513771-40-01 chronic renal failure requiring kidney transplantation 2025-03-03
Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1 Recruiting

2023-509748-89-00 Facioscapulohumeral muscular dystrophy (FSHD) 2025-02-19
Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refrac… Recruiting

2024-520436-15-00 High Risk and/or relapsed/refractory Neuroblastoma and 2025-02-18
A Phase 1/2 Dose-Exploration and Dose-Expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients with Alpha-1 Antitry… Recruiting

2023-509256-34-00 Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung D 2025-02-06
Safety and tolerability of TOP-N53 applied on digital ulcers in patients with systemic sclerosis Recruiting

2024-511861-12-00 Digital ulcers in systemic sclerosis 2025-02-04
A trial in patients suffering from a specific form of an eye disorder called retinitis pigmentosa Recruiting

2023-504383-42-00 Retinitis Pigmentosa (due to CNGA1 mutation) 2025-02-02
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) an… Recruiting

2024-512900-20-00 Non-muscle invasive bladder cancer (NMIBC) 2025-01-30
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting

2023-507141-28-00 Solid tumor 2025-01-29
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration Recruiting

2024-512264-66-00 Solid Tumors 2025-01-29
IMMUNOTHERAPY WITH DIFFERENTIATED T CELLS, ADULTS, AUTOLOGOUS, FROM PERIPHERAL BLOOD, SELECTED BY CD62L EXPRESSION, EXPANDED AND TRANSDUCED … Recruiting

2024-519790-19-00 Relapsed/refractory large B-cell non-Hodgkin lymphoma, 2025-01-24
Inmmunotherapy with peripheral blood, autologous, a dult T cells, expanded and transduced (gene modified) with a lentiviral vector expressin… Recruiting

2024-515624-36-00 Refractary or relapse non-Hodgkin T CD30+ lymphoma. 2024-12-17
A Phase 1/2 Study of VX-670 in Adult Subjects with Myotonic Dystrophy Type 1 Recruiting

2023-506028-10-00 Myotonic Dystrophy 2024-12-11
An open-label, non-randomised safety and tolerability Proof of Concept Trial to examine multiple dosing addition of glycocholate (GC) and bu… Recruiting

2024-511124-14-00 Postoperative obesity 2024-12-10
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Advance solid tumors 2024-11-14
A study to test if different doses of D3S-001 used on its own or in combination with other anti-cancer medicines is safe and tolerable in pe… Recruiting

2023-508517-16-00 Advanced Solid Tumors with a KRAS p.G12C Mutation 2024-11-10
New adjuvant vaccine in glioblastoma, a Phase 1/2a study (NAVIG-1) Recruiting

2024-514567-26-00 glioblastoma 2024-11-08
Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO) Recruiting

2023-508254-26-00 Primary aldosteronism 2024-11-06